Eiger Mountains
Keyword Search
 
2018 | 2017 | 2016
DateTitle 
06/04/18Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™
PALO ALTO, Calif., June 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program as well as an update on the Phase 3 D-LIVR study will be presented at Global Hepatitis Summit 2018™ in Toronto, Canada, June 14-17, 2018.  Events at... 
Printer Friendly Version
05/30/18Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
PALO ALTO, Calif., May 30, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will present a corporate update at Jefferies 2018 Global Healthcare Conference on June 5th at 4:00 PM ET.  The corporate update will include a discussion of recent progress across all Eiger programs including Hepatitis Delta Virus (HDV), Hutchinson-Gilford Proge... 
Printer Friendly Version
05/24/18Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
PALO ALTO, Calif., May 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced that it is selling 3,200,000 shares of its common stock in the public offering at an offering price of $12.50 per share.  In connection with the offering, Eiger h... 
Printer Friendly Version
05/23/18Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., May 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of its common stock.  Eiger intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and cond... 
Printer Friendly Version
05/16/18Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
- Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif., May 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside the United States and Canada, to include rights to develop the investigational farnesyltransferase inhibit... 
Printer Friendly Version
05/11/18Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
- Hepatitis Delta Virus (HDV) Program Moving into Phase 3 - Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018 - Existing Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., May 11, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months ended March 31, 2018 and provided a business update. ... 
Printer Friendly Version
04/17/18Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
PALO ALTO, Calif., April 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver Congress™ 2018, in Paris, France.  A subanalysis of the LOWR-2 study reveals high response rates to LNF all-oral therapy in patients with low baseline viral loads ≤ 4 logs.  After 24 weeks of treatment, all-oral lonafarnib-based ... 
Printer Friendly Version
04/02/18Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif., April 2, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in April. H.C. Wainwright Global Life Science Conference at Le Meridien in Monte Carlo, Monaco. Eiger will present a corporate overview and business update on April 9, 3:50 pm – 4:15 pm CET. Eiger will h... 
Printer Friendly Version
03/26/18Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif., March 26, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of subcutaneous (SC) exendin 9-39 in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels (hypoglycemia) known as post-bariatric hypoglycemia (PBH).  PREVENT will target enrollment of 20 PBH pat... 
Printer Friendly Version
03/21/18Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
- Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 PALO ALTO, Calif., March 21, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today positive FDA guidance from a face to face discussion on the Hepatitis Delta Virus (HDV) program in February, including agreement that a single, registration trial in HDV can support an NDA filing.  ... 
Printer Friendly Version
03/12/18Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
- Hepatitis Delta Virus Program Moving into Phase 3 in 2018 - Phase 2 Clinical Results Planned from Three Pipeline Programs in 2018 - Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., March 12, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months and year ended December 31, 2017 and provided a business update. ... 
Printer Friendly Version
03/06/18Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
PALO ALTO, Calif., March 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at three upcoming conferences in March. China Healthcare Investment & Partnering Symposium (CHIPS), March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China. Eiger will present a... 
Printer Friendly Version
03/05/18Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
PALO ALTO, Calif., March 5, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at The International Liver Congress™ meeting in Paris, France, April 11 to 15, 2018. Accepted abstracts to The International Liver Congress™ are listed below: Yurdaydin, C. et al; "Subanalysis of the LOWR HDV-2 study reveals high res... 
Printer Friendly Version
02/06/18Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
PALO ALTO, Calif., Feb. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming conferences in February. 2018 BIO CEO & Investor Conference, February 12, 2018 at 3:00 pm ET at the New York Marriott Marquis in New York City. Eiger will host one-o... 
Printer Friendly Version
01/16/18Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
- End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif., Jan. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today Phase 2 LIBERTY study results in pulmonary arterial hypertension (PAH) that demonstrated no improvement overall or in key subgroups for both the primary efficacy endpoi... 
Printer Friendly Version
01/08/18Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
PALO ALTO, Calif., Jan. 8, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr. Mayer is a pharmaceutical industry veteran with broad commercial experience which spans over two decades in large pharma and specialty pharma across oncology, inflammatory disease, pulmonary disease, dermatology and rare diseases, with multiple ... 
Printer Friendly Version
01/04/18Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
- ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif., Jan. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 ULTRA study.  ULTRA is a randomized, placebo-controlled study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limb(s).  There is currently no FDA approv... 
Printer Friendly Version
01/03/18Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
PALO ALTO, Calif., Jan. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer.  Dr. Apelian's clinical development and regulatory experience spans 17 years between large pharma and biotechnology companies in all phases of development ranging from discovery to registration, across m... 
Printer Friendly Version
01/02/18Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
PALO ALTO, Calif., Jan. 2, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO, will present a corporate update at Biotech Showcase™ 2018 on January 8th at 2:00 pm PT at the Hilton San Francisco (Franciscan – B Ballroom Level).  The corporate update will include a discussion of recent progress across all Eiger programs including Hepatitis ... 
Printer Friendly Version